Home/Pipeline/NOX-A12

NOX-A12

Pancreatic Cancer

Phase 2Active

Key Facts

Indication

Pancreatic Cancer

Phase

Phase 2

Status

Active

Company

TME Pharma

About TME Pharma

TME Pharma is a Berlin-based, publicly traded biotech advancing a novel approach to cancer treatment by targeting the tumor microenvironment. Its lead asset, NOX-A12, is a CXCL12-neutralizing Spiegelmer in Phase 2 development for glioblastoma, showing promising survival data in combination regimens. The company is pre-revenue, with a financial runway extending beyond 12 months as of early 2026, and faces the critical challenges of advancing late-stage trials and securing additional funding or partnerships.

View full company profile

Therapeutic Areas

Oncology Glioblastoma Pancreatic Cancer

Other Pancreatic Cancer Drugs

Drug	Company	Phase	Status
Ampligen® (rintatolimod)	AIM ImmunoTech	Early Access Program	Active - Approved in the Netherlands at Erasmus MC
HBM9027	Harbour BioMed	Phase 1	Active (Global)
Small-Molecule Therapeutic	AIkido Labs	Pre-clinical	Active
AHPBA IRE Registry	AngioDynamics	Post-Market Registry	Active
SIMBs + Immunotherapy	Advanced Microbubbles	Pre-clinical	Validated in preclinical studies
CLS-014	CLS Therapeutics	Pre-clinical	Lead candidate
SOMA Platform	Coherence Neuro	Pre-clinical	Pipeline expansion launched in 2024
NP-G2-044	Novita Pharmaceuticals	Phase 2a	Orphan Drug Designated (Jan 2026)
Pritumumab (PTB)	Nascent Biotech	Phase II (Planned)	Exploratory
Pancreatic Cancer Test	Mosaique Diagnostic	Development	Active
Iontophoretic System	Continuity Biosciences	Pre-clinical	Active
Lixumistat (IM156)	ImmunoMet Therapeutics	Phase 1b	Active